IDT v1.0
Research type
Research Study
Full title
Improving Diagnosis and Treatment of advanced prostate cancer through better imaging with Whole-Body Magnetic Resonance Imaging with diffusion weighted imaging
IRAS ID
293675
Contact name
Nina Tunariu
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
2 years, 10 months, 2 days
Research summary
Metastatic Advanced Prostate Cancer (APC) occurs when cancer spreads from the prostate to other parts of the body (bones, lymph nodes or other organs), with bones being the commonest site of spread in prostate cancer. These cancer growths are called metastases. APC metastases are diverse (heterogeneous) in their growth pattern, such that not all metastases will respond to the same treatment.
The aim of this study is to provide clinical evidence to determine if Whole Body Magnetic Resonance Imaging (WBMRI) with a novel technique called diffusion-weighted imaging (DWI) can improve current treatment for APC patients, allowing for early identification of disease progression or treatment response, hence facilitating clinical decision-making and leading to improvement in patient care. The IDT study includes two retrospective analysis and a single centre prospective observational study for APC patients.
The prospective arm of the study will aim to provide clinical evidence to determine if WBMRI is able to provide reliable information regarding the killing of cancer cells approximately three months after starting treatment. The WBMRI information will be compared with the bone biopsy results and used to explore how a WBMRI scan can give doctors more information on the progression and evolution of the disease. This information will be used to improve further therapies for patients with advanced prostate cancer.REC name
London - Bloomsbury Research Ethics Committee
REC reference
21/LO/0605
Date of REC Opinion
4 Oct 2021
REC opinion
Further Information Favourable Opinion